Form 8-K - Current report:
SEC Accession No. 0001420720-24-000027
Filing Date
2024-06-05
Accepted
2024-06-05 16:10:59
Documents
17
Period of Report
2024-05-31
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20240531x8k.htm   iXBRL 8-K 46549
2 EX-4.1 ibio-20240531xex4d1.htm EX-4.1 114810
3 EX-99.1 ibio-20240531xex99d1.htm EX-99.1 9591
4 EX-99.2 ibio-20240531xex99d2.htm EX-99.2 304833
  Complete submission text file 0001420720-24-000027.txt   651072

Data Files

Seq Description Document Type Size
5 EX-101.SCH ibio-20240531.xsd EX-101.SCH 4157
6 EX-101.DEF ibio-20240531_def.xml EX-101.DEF 3256
7 EX-101.LAB ibio-20240531_lab.xml EX-101.LAB 13973
8 EX-101.PRE ibio-20240531_pre.xml EX-101.PRE 10316
20 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240531x8k_htm.xml XML 4644
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 241022114
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)